Recombinant human growth hormone (Xiamen Amoytop Biotec)

重组人生长激素（厦门特宝）

Report date: 2022/01/17 12:14:22

Base Information

Drug NameRecombinant human growth hormone (Xiamen Amoytop Biotec)
Drug Alias Name重组人生长激素-厦门特宝生物工程股份有限公司rhGH (Xiamen Amoytop Biotec)
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionGrowth hormone receptor agonists
TargetsGrowth hormone receptor
Therapy Area/IndicationsGrowth hormone deficiencyIdiopathic short statureTurner Syndrome +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesXiamen Amoytop Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesXiamen Amoytop Biotech Co LtdXiamen Bosai Gene Transcription Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsGrowth hormone deficiencyIdiopathic short statureTurner Syndrome +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeH01AC01
Related LinksN/A